Anti-Human CD20 [Clone 2H7] — Purified in vivo PLATINUM™ Functional Grade
Anti-Human CD20 [Clone 2H7] — Purified in vivo PLATINUM™ Functional Grade
Product No.: C1651
Clone 2H7 Target CD20 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names MS4A1, B1, Bp35 Isotype Mouse IgG2b κ Applications CyTOF® , FC , in vivo , WB |
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Recommended Isotype Controls Recommended Dilution Buffer Immunogen Human tonsillar B cells Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2828708 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this 2H7 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application. WB The suggested concentration for this 2H7 antibody for use in western blotting is 1-10 μg/ml. Additional Applications Reported In Literature ? CyTOF® Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone 2H7 recognizes an epitope on human CD20. Background CD20 is a 33-37 kD transmembrane-spanning phosphoprotein that facilitates optimal B-cell immune response against T-independent antigens. It can exist in a complex with MHC class I, MHC class II, CD53, CD81, and CD82. However, CD20 can also form homo-oligomers. It has been suggested that homo-oligomerization of CD20 forms calcium ion channels in the plasma membrane of B cells. CD20 can be useful in diagnosing B-cell lymphomas and leukemias, and is the target of mAbs in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. Interestingly, studies show a link between the immune system's B cells and diabetes mellitus in which anti-CD20 antibodies rendered the T cell antibodies dysfunctional and, hence, unable to cause insulin desensitivity by a B cell antibody-modulated autoimmune response. Antigen Distribution CD20 is present on human pre B lymphocytes and on B lymphocytes, except on plasma cells, and is expressed in tandem with surface IgM. It is also expressed in some follicular dendritic cells and at low levels on a T cell subset. Ligand/Receptor Src family tyrosine kinases, MHC class I, II, CD53, CD81, CD82 NCBI Gene Bank ID UniProt.org Research Area Costimulatory Molecules . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. The clone 2H7 is a monoclonal antibody that specifically targets the human CD20 antigen, which is expressed on the surface of B cells. In studies involving humanized mice, this antibody is commonly used for:
Commonly Used Antibodies and Proteins Alongside 2H7The monoclonal antibody 2H7 is specified as an anti-human CD20 reagent and is used extensively to identify and study B cells in both research and therapeutic contexts. It is also employed as a positive control in antibody panels. In Immunological ResearchRituximab is one of the most frequently cited antibodies used in conjunction with 2H7 in the literature, particularly because both target the CD20 antigen on B cells. They are often compared for their binding affinities and epitope recognition, with studies detailing the subtle structural differences in how each interacts with CD20. Isotype control antibodies are commonly used alongside 2H7 as negative controls to ensure specificity in experimental assays. These controls help distinguish specific binding (due to 2H7) from nonspecific interactions. F8 is another antibody mentioned in contexts involving 2H7, such as the construction of chelating recombinant antibodies (CRAbs) for targeted therapy applications. However, F8 targets a different protein (fibronectin extra domain A, not CD20), so its co-usage with 2H7 is a technical (e.g., bioconjugation, targeting, or imaging) rather than a functional or analytical overlap. In Microbiology and Infectious DiseaseInterestingly, 2H7 is also the name of a monoclonal antibody targeting Staphylococcus aureus surface antigen A (SasA) in some microbiology literature. In these studies, isotype control antibodies are again used as negative controls to validate the specificity of 2H7 binding and its functional effects (e.g., opsonophagocytic killing). Summary Table
Key Points
There is no evidence in the provided literature that other B7 family proteins or unrelated antibodies/proteins are routinely used alongside 2H7 in mainstream immunological research. The most common companions are rituximab (for CD20 targeting), isotype controls (for specificity), and, in niche applications, F8 (for advanced targeting strategies). Clone 2H7 is a widely cited mouse monoclonal antibody that specifically recognizes the human CD20 cell surface antigen, a 33–37 kDa non-glycosylated phosphoprotein expressed on most mature B cells and many B-cell malignancies. Key findings from scientific citations of clone 2H7 include:
In summary, citations of clone 2H7 in scientific literature consistently demonstrate its reliability as a tool for detecting and depleting human CD20+ cells, its foundational role in B cell research, and its relevance to therapeutic antibody design and cancer immunotherapy. OverviewThe dosing regimen of the anti-CD20 monoclonal antibody clone 2H7 (mouse IgG2b) in mouse models is not strongly standardized and can vary considerably depending on the specific mouse model, experimental objectives, and the balance between efficacy and toxicity. General Dosing Guidance
Factors Influencing Dosing
Considerations for Humanized Mouse ModelsHumanized mice (e.g., THX or Hu-NSG) are increasingly used to model human immune responses, but the literature does not provide a consensus on 2H7 dosing for these specific strains. Researchers must empirically determine the optimal dose based on the degree of human immune cell engraftment, target antigen (human vs. mouse CD20), and the experimental endpoint. Summary Table
ConclusionDosing of clone 2H7 in mouse models typically ranges from 100–250 µg per mouse every 3–4 days by intraperitoneal injection, but must be tailored to the specific mouse strain, disease model, and experimental objectives. For humanized or immunodeficient mice, regimens should be empirically optimized, as these models present unique challenges and opportunities for immunotherapy research. No standardized protocol for 2H7 in humanized mice was found in the current literature; thus, pilot studies are recommended to establish optimal dosing in these advanced models. References & Citations1. Stashenko, P. et al. (1980) J. Immunol. 125:1678
2. Fang, D. et al. (2005) Cancer Res. 65:9328
3. Bubien, J. K. et al. (1993) J. Cell Biol. 121:1121
4. White, M. W. et al. (1991) J. Immunol. 146:846
5. Cragg, M. S. et al. (2005) Curr. Dir. Autoimmun. 8:140 Technical ProtocolsCertificate of Analysis |
Related Products
Prod No. | Description |
|---|---|
C1682 | |
C1678 | |
C1680 | |
C1895 | |
C1896 | |
C1651 |
Formats Available
Prod No. | Description |
|---|---|
C1682 | |
C1602 | |
C1653 | |
C1654 | |
C1674 | |
C1675 | |
C1676 | |
C1678 | |
C1680 | |
C1895 | |
C1652 | |
C1896 | |
C1651 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
